Report ID: SQMIG35H2249
Report ID:
SQMIG35H2249 |
Region:
Global |
Published Date: July, 2024
Pages:
260
|
Tables:
128 |
Figures:
77
In October 2023, the subsidiary of Gilead, Kite and Epicrispr Biotechnologies, announced a research collaboration and licensing agreement to apply the gene regulation platform of the latter in the production of advanced cancer cell therapies.
In September 2023, Merck KGaA formed collaborations with BenevolentAI and Exscientia—two companies that use AI for drug discovery in oncology, neurology, and immunology—which may result in the emergence of novel candidates up for clinical development.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35H2249